Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Incyte Corp (NQ: INCY ) 65.74 -1.08 (-1.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Incyte Corp < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets September 18, 2024 Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... Via Benzinga Topics Intellectual Property Exposures Intellectual Property Wall Street Lower Ahead Of Interest Rate Move September 18, 2024 Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today. Via Talk Markets Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers September 16, 2024 Intel kept running late on yet another big deal. Via Investor's Business Daily Topics Stocks Exposures US Equities Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings) September 03, 2024 Via Benzinga Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study August 16, 2024 Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in relapsed follicular lymphoma patients, showing positive progression-free... Via Benzinga Exposures Product Safety Analyst Expectations For Incyte's Future August 15, 2024 Via Benzinga Analyst Ratings For Incyte July 26, 2024 Via Benzinga Looking for growth without the hefty price tag? Consider NASDAQ:INCY. July 22, 2024 INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably. Via Chartmill FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication August 15, 2024 The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at least two prior therapies, providing new hope for those with this serious... Via Benzinga Exposures Product Safety After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial July 31, 2024 MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 2024 conference. Via Benzinga Topics Death Exposures Death Incyte's Q2 Earnings: Wider Than Expected Loss, Pipeline Review, Lifts Jakafi Sales Guidance July 30, 2024 Incyte reported Q2 revenue of $1.04 billion, beating consensus, with Jakafi revenue at $705.9 million and Opzelura revenue up 52%. Despite an adjusted EPS loss, the company updated its 2024 Jakafi... Via Benzinga NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. July 10, 2024 INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals. Via Chartmill S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday? July 09, 2024 The S&P 500 index climbed to new all-time highs, rising 0.3% during Tuesday’s session, aiming for a potential sixth consecutive positive close and remaining resilient after Fed Chair Jerome Powell‘s... Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities NASDAQ:INCY is not too expensive for the growth it is showing. July 01, 2024 In the world of growth stocks, INCYTE CORP (NASDAQ:INCY) shines as a value proposition. Via Chartmill The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024 July 09, 2024 The stock market watches this investing guru's picks closely but these may be the best undervalued Cathie Wood stocks in her ETFs. Via InvestorPlace 7 Cheap Biotech Stocks With Major Upside Potential July 09, 2024 While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. Via InvestorPlace 3 Highly Rated Biotech Stocks for Your July Buy List July 05, 2024 Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. Via InvestorPlace This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday July 02, 2024 Via Benzinga Stocks Chop As Wall Street Unpacks Powell Comments July 02, 2024 Stocks are mixed at midday, as investors weigh remarks from Federal Reserve Chair Jerome Powell. Via Talk Markets Topics Economy Exposures Interest Rates Analyst Expectations For Incyte's Future June 18, 2024 Via Benzinga Despite its growth, NASDAQ:INCY remains within the realm of affordability. June 10, 2024 Don't overlook INCYTE CORP (NASDAQ:INCY)—a stock with solid growth prospects and a reasonable valuation. Via Chartmill 9 Analysts Have This To Say About Incyte May 23, 2024 Via Benzinga 7 Undervalued Biotech Stocks to Buy for Big-Time Returns July 01, 2024 The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. Via InvestorPlace For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. June 19, 2024 In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals. Via Chartmill Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers June 13, 2024 The Nasdaq 100 index posted its fourth consecutive session in the green on Thursday, closing at 19,576 points and reaching all-time highs. Via Benzinga Topics Stocks Exposures US Equities NASDAQ:INCY is showing decent growth, but is still valued reasonably. May 17, 2024 INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing. Via Chartmill 10 Health Care Stocks Whale Activity In Today's Session June 04, 2024 Via Benzinga When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. May 29, 2024 INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI May 24, 2024 Hedge funds are looking for high-return opportunities beyond the mega-cap tech giants preferring to focus on cyclical sectors and AI. Via Benzinga Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday? May 13, 2024 Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days. Via Benzinga Topics Economy Exposures Interest Rates < Previous 1 2 3 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.